https://www.thebodypro.com/category/triumeq-pro/tag/conference-coverage

The Latest

injectable

The Monthly Injectable HIV Drug Works Just as Well When Given Every Two Months

Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.

By Sony Salzman
Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman
Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial Img

Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial

A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.

By Mark Mascolini
Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment Img

Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq.

By Project Inform
Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load Img

Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load

Paul Sax, M.D., recaps an important study presented at ICAAC 2015, which highlighted 24-week results for patients switching to abacavir/dolutegravir/lamivudine (Triumeq).

By Paul E. Sax, M.D. for NEJM Journal Watch